Article Information
History
- May 3, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Mars Stone1,2,*,
- Clara Di Germanio1,
- David J. Wright3,
- Hasan Sulaeman1,
- Honey Dave1,
- Rebecca V. Fink3,
- Edward P. Notari4,
- Valerie Green5,
- Donna Strauss6,
- Debra Kessler6,
- Mark Destree7,
- Paula Saa4,
- Phillip C. Williamson1,5,
- Graham Simmons1,2,
- Susan L. Stramer4,
- Jean Opsomer3,
- Jefferson M. Jones8,
- Steven Kleinman9,
- Michael P. Busch1,2,*,
- for the NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P)
- 1Vitalant Research Institute (VRI), San Francisco, CA
- 2Department of Laboratory Medicine, University of California, San Francisco, CA
- 3Westat, Rockville, MD
- 4American Red Cross (ARC), Gaithersburg, MD
- 5Creative Testing Solutions (CTS), Tempe, AZ
- 6New York Blood Center (NYBC), New York, NY
- 7BloodWorks Northwest, Seattle, WA
- 8Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia
- 9University of British Columbia, Victoria, BC, Canada
- ↵*Corresponding author: Michael P. Busch MD, PhD. Address: Vitalant Research Institute, 270 Masonic Avenue, San Francisco, CA, United States 94118. Phone: 1-415-354-1389. Fax: 1-415-567- 5899. Email: mbusch{at}vitalant.org, Alternate corresponding author: Mars Stone, PhD. Vitalant Research Institute, 270 Masonic Avenue, San Francisco, CA, United States 94118. Phone: 1-415-354-1389. Fax: 1-415-567-5899. Email: mstone{at}vitalant.org
Posted May 03, 2021.
Use of U.S. Blood Donors for National Serosurveillance of SARS-CoV-2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program
